NightHawk Biosciences(US:NHWK)2025-04-30 20:01Company Overview - The company is a contract development and manufacturing organization (CDMO) providing a comprehensive range of biologics manufacturing services, including CGMP clinical and commercial manufacturing, with operations commencing in September 2022 at the San Antonio, TX facility[17]. - In 2023, the company shifted its priorities towards biomanufacturing capabilities, refocusing resources away from research and divesting clinical stage oncology assets, including HS-110 and PTX-35[18]. Stock and Trading Status - The company’s common stock is currently suspended from trading on the NYSE American and is trading on the OTC Markets Pink Limited exchange, with an ongoing review for delisting due to low stock price[19][20]. - A reverse stock split of 1-for-200 was executed on July 17, 2024, affecting the number of shares and corresponding adjustments to convertible securities and equity awards[25]. - The company’s common stock began trading under the new ticker symbol "SCPX" on February 6, 2024, following a name change to Scorpius Holdings, Inc.[71]. - The company’s stock price has shown significant volatility, with a low of $0.295 per share on December 18, 2024, and a high of $89.94 per share on January 5, 2024, closing at $0.33 per share on December 31, 2024[155]. - Future delisting from the NYSE American is expected to negatively affect the company's ability to attract investors and raise capital[143]. Financial Performance - For the year ended December 31, 2024, the company reported net losses of approximately $34.3 million, compared to $46.8 million for the year ended December 31, 2023[81]. - The company had an accumulated deficit of $287.2 million as of December 31, 2024, up from $254.4 million as of December 31, 2023[85]. - The company utilized net cash of approximately $26.0 million from operating activities during the year ended December 31, 2024, compared to $31.5 million for the year ended December 31, 2023[85]. - The company expects to incur significant expenses and continued losses from operations for the foreseeable future, with no assurance of achieving profitability[90]. - The company has identified material weaknesses in its internal control over financial reporting, which raises concerns about the reliability of its financial statements[93]. - The company has experienced market-wide liquidity problems in the past, which could recur due to adverse developments in the financial services industry[151]. Revenue and Customer Dependency - The company has generated revenue from multiple biotechnology, pharmaceutical, and university customers, with deposits classified as deferred revenue to be recognized upon meeting performance obligations[31]. - Revenue from major customers for the year ended December 31, 2024, included Customer A at 37% and Customer B at 16%, while for 2023, Customer A accounted for 70% and Customer C for 12%[65]. - For the year ended December 31, 2024, revenue from two customers accounted for 53% of total revenue of $6.2 million, down from 82% of total revenue of $7.0 million in 2023[108]. - One customer represented 37% of total revenue in 2024, compared to 70% in 2023, indicating a significant dependency on a limited customer base[108]. - The company’s major customers' revenue concentration poses a risk, as the loss of any primary customer could materially affect its financial condition[68]. Operational Strategy and Development - The company plans to expand its CDMO service offerings, including enhanced microbial and mammalian development and manufacturing services, to attract emerging biotechnology and pharmaceutical companies[36]. - The company aims to maximize commercial opportunities for Scorpius Bio, launched in September 2022, by offering biomanufacturing capacity to third parties on a fee-for-service model[36]. - The company is exploring partnerships for licensing and collaborative relationships to enhance its market position in contract development and manufacturing[36]. - The company aims to enhance its in-house biomanufacturing capabilities to reduce reliance on third-party vendors and support its operations in the growing CDMO market[200]. - The company does not expect to generate significant revenue from CDMO services for several years as it is a new entrant in that line of business[83]. Compliance and Regulatory Risks - Compliance with regulatory requirements is critical, with potential significant costs associated with noncompliance impacting financial conditions[61]. - The company maintains environmental and industrial safety compliance programs due to the use of hazardous materials in manufacturing[62]. - Regulatory approval is critical for the company's success; delays or failures in customer product approvals could negatively affect revenue and profitability[116]. - The company faces potential liabilities related to CDMO services, including clinical trial liability claims, which could impact its financial stability[120]. - Compliance with regulatory requirements is essential; noncompliance could lead to significant costs and operational disruptions[121]. Intellectual Property and Competitive Risks - The company has no patents but has pending patent applications and continues to develop proprietary know-how and trade secrets[55]. - The company has limited protection for its intellectual property, which could adversely affect its competitive position and operating results[130]. - There are significant risks associated with potential infringement of third-party intellectual property rights, which could lead to costly litigation and diversion of resources[135]. - The company may face challenges in enforcing its intellectual property rights in foreign jurisdictions, potentially allowing competitors to capture market share[131]. Human Resources and Management - The company has a total of 90 employees as of December 31, 2024, with 51 in CDMO operations and 5 in Sales and Marketing[76]. - The company anticipates needing to attract and retain highly skilled personnel to pursue its CDMO strategy, which is competitive[78]. - The company is dependent on key executive officers and scientific advisors, and the loss of their expertise could delay product development and adversely affect operating results[158]. - The company may struggle to hire additional qualified personnel due to intense competition in the biopharmaceutical sector, which is critical for its growth[159]. Financing and Capital Structure - The company anticipates needing additional financing to fund operations through April 2025, with potential dilution of stockholders if equity securities are issued[86]. - The company is currently evaluating various financing options for its operations, including cash on hand and potential equity financings, but lacks any funding commitments as of the report date[202]. - The company closed the March 2024 Offering, issuing 50,000 shares at $30.00 per share, resulting in net proceeds of $1.2 million[205]. - The May 2024 Offering raised approximately $6.0 million by selling 149,100 units and 150,900 pre-funded units at $20.00 each, with warrants exercisable at $24.00 per share[206]. - The August 2024 Offering generated approximately $14.4 million in gross proceeds from the sale of 2,428,000 shares and 11,947,000 pre-funded warrants, with offering expenses of $1.3 million[208]. - The company issued a non-convertible promissory note for $225,000 at a 5% interest rate, maturing on December 15, 2024, or upon a corporate event[209]. - The December 2024 Offering included secured convertible notes totaling $13,388,889, with net proceeds of approximately $3.0 million after repurchasing August 2024 pre-funded warrants[211]. - The December 2024 Secured Convertible Notes bear a 9% annual interest rate, maturing on December 6, 2027, and are convertible at an initial price of $0.50, adjusted to $0.25 in February 2025[213][214]. Market and Economic Conditions - Changes in global economic conditions, including geopolitical tensions and trade policies, may adversely impact the company's business and financial results[146]. - The company is facing increased operating costs due to rising inflation, particularly in the United States and United Kingdom, which could impact demand and pricing for its products[150]. - Fluctuations in foreign currency exchange rates may adversely affect financial results, especially with international sales[128]. Cybersecurity and IT Risks - The company relies heavily on information technology systems, making it vulnerable to cyber-attacks and data breaches that could impact operations and reputation[145]. - Scorpius Holdings, Inc. has implemented a comprehensive cyber risk management program to address cybersecurity threats, partnering with third-party providers for services such as vulnerability scanning and incident response[173]. Real Estate and Facilities - The company has entered into a lease for 15,996 square feet of office and laboratory space in Morrisville, North Carolina, with a starting monthly rent of $43,655, increasing by 3% annually[177]. - Scorpius Holdings has moved its principal offices to San Antonio, Texas, and has multiple leases for facilities, including a mammalian facility with a starting monthly rent of $50,360, increasing by 3% annually, expiring in September 2037[181]. - Scorpius Holdings has recorded a right-of-use asset and corresponding lease liability for its facilities, indicating significant financial commitments related to its operational infrastructure[181]. Shareholder Engagement and Dividends - As of April 30, 2025, there were approximately 12 stockholders of record for the company's common stock, reflecting limited shareholder engagement[190]. - The company has never paid cash dividends on its common stock and does not anticipate doing so in the foreseeable future, with dividend decisions at the discretion of the Board of Directors[191].